NGL Fine-Chem Limited (NGLFINE) - Net Assets
Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) has net assets worth Rs3.29 Billion INR (≈ $35.60 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs5.45 Billion ≈ $58.99 Million USD) and total liabilities (Rs2.16 Billion ≈ $23.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See NGL Fine-Chem Limited balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.29 Billion |
| % of Total Assets | 60.35% |
| Annual Growth Rate | 22.18% |
| 5-Year Change | 62.01% |
| 10-Year Change | 462.67% |
| Growth Volatility | 12.37 |
NGL Fine-Chem Limited - Net Assets Trend (2009–2026)
This chart illustrates how NGL Fine-Chem Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see NGL Fine-Chem Limited market capitalisation.
Annual Net Assets for NGL Fine-Chem Limited (2009–2026)
The table below shows the annual net assets of NGL Fine-Chem Limited from 2009 to 2026. Also explore NGLFINE net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs3.29 Billion ≈ $35.60 Million |
+16.57% |
| 2025-03-31 | Rs2.82 Billion ≈ $30.54 Million |
+7.54% |
| 2024-03-31 | Rs2.63 Billion ≈ $28.40 Million |
+18.01% |
| 2023-03-31 | Rs2.23 Billion ≈ $24.07 Million |
+9.51% |
| 2022-03-31 | Rs2.03 Billion ≈ $21.98 Million |
+31.57% |
| 2021-03-31 | Rs1.54 Billion ≈ $16.70 Million |
+56.08% |
| 2020-03-31 | Rs989.61 Million ≈ $10.70 Million |
+7.42% |
| 2019-03-31 | Rs921.23 Million ≈ $9.96 Million |
+27.87% |
| 2018-03-31 | Rs720.42 Million ≈ $7.79 Million |
+23.12% |
| 2017-03-31 | Rs585.12 Million ≈ $6.33 Million |
+32.34% |
| 2016-03-31 | Rs442.15 Million ≈ $4.78 Million |
+34.73% |
| 2015-03-31 | Rs328.16 Million ≈ $3.55 Million |
+33.70% |
| 2014-03-31 | Rs245.44 Million ≈ $2.65 Million |
+22.62% |
| 2013-03-31 | Rs200.15 Million ≈ $2.16 Million |
+17.01% |
| 2012-03-31 | Rs171.06 Million ≈ $1.85 Million |
+6.52% |
| 2011-03-31 | Rs160.59 Million ≈ $1.74 Million |
+17.66% |
| 2010-03-31 | Rs136.48 Million ≈ $1.48 Million |
+24.82% |
| 2009-03-31 | Rs109.35 Million ≈ $1.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NGL Fine-Chem Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5707.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs3.24 Billion | 98.39% |
| Common Stock | Rs30.89 Million | 0.94% |
| Other Components | Rs22.02 Million | 0.67% |
| Total Equity | Rs3.29 Billion | 100.00% |
NGL Fine-Chem Limited Competitors by Market Cap
The table below lists competitors of NGL Fine-Chem Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Franklin Universal Closed Fund
NYSE:FT
|
$184.97 Million |
|
Nam Kim Steel JSC
VN:NKG
|
$185.00 Million |
|
Lithium Royalty Corp
TO:LIRC
|
$185.06 Million |
|
XRF Scientific Ltd
AU:XRF
|
$185.15 Million |
|
TerrAscend Corp
F:TED
|
$184.94 Million |
|
SPACSphere Acquisition Corp. Class A Ordinary Shares
NASDAQ:SSAC
|
$184.81 Million |
|
D2L Inc
TO:DTOL
|
$184.69 Million |
|
Ascom Holding AG
SW:ASCN
|
$184.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NGL Fine-Chem Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 2,824,346,000 to 3,292,295,000, a change of 467,949,000 (16.6%).
- Net income of 481,267,000 contributed positively to equity growth.
- Dividend payments of 10,812,000 reduced retained earnings.
- Other comprehensive income decreased equity by 20,929,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs481.27 Million | +14.62% |
| Dividends Paid | Rs10.81 Million | -0.33% |
| Other Comprehensive Income | Rs-20.93 Million | -0.64% |
| Other Changes | Rs18.42 Million | +0.56% |
| Total Change | Rs- | 16.57% |
Book Value vs Market Value Analysis
This analysis compares NGL Fine-Chem Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 156.40x to 5.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-03-31 | Rs17.70 | Rs2768.20 | x |
| 2010-03-31 | Rs22.09 | Rs2768.20 | x |
| 2011-03-31 | Rs25.99 | Rs2768.20 | x |
| 2012-03-31 | Rs27.69 | Rs2768.20 | x |
| 2013-03-31 | Rs32.40 | Rs2768.20 | x |
| 2014-03-31 | Rs39.73 | Rs2768.20 | x |
| 2015-03-31 | Rs53.12 | Rs2768.20 | x |
| 2016-03-31 | Rs71.57 | Rs2768.20 | x |
| 2017-03-31 | Rs94.71 | Rs2768.20 | x |
| 2018-03-31 | Rs116.61 | Rs2768.20 | x |
| 2019-03-31 | Rs149.11 | Rs2768.20 | x |
| 2020-03-31 | Rs160.18 | Rs2768.20 | x |
| 2021-03-31 | Rs250.01 | Rs2768.20 | x |
| 2022-03-31 | Rs328.94 | Rs2768.20 | x |
| 2023-03-31 | Rs360.23 | Rs2768.20 | x |
| 2024-03-31 | Rs425.11 | Rs2768.20 | x |
| 2025-03-31 | Rs457.09 | Rs2768.20 | x |
| 2026-03-31 | Rs532.91 | Rs2768.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NGL Fine-Chem Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.62%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.61%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.66x
- Recent ROE (14.62%) is below the historical average (17.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 15.39% | 6.83% | 1.21x | 1.86x | Rs5.90 Million |
| 2010 | 19.82% | 9.72% | 1.10x | 1.86x | Rs13.40 Million |
| 2011 | 15.04% | 6.89% | 1.07x | 2.05x | Rs8.10 Million |
| 2012 | 6.12% | 2.90% | 0.97x | 2.17x | Rs-6.64 Million |
| 2013 | 14.53% | 5.24% | 1.17x | 2.37x | Rs9.08 Million |
| 2014 | 18.45% | 5.74% | 1.41x | 2.28x | Rs20.74 Million |
| 2015 | 25.38% | 9.43% | 1.33x | 2.03x | Rs50.48 Million |
| 2016 | 25.78% | 11.84% | 1.24x | 1.75x | Rs69.77 Million |
| 2017 | 24.34% | 14.22% | 0.99x | 1.73x | Rs83.88 Million |
| 2018 | 17.48% | 11.35% | 0.86x | 1.79x | Rs53.89 Million |
| 2019 | 21.85% | 13.35% | 1.06x | 1.54x | Rs109.15 Million |
| 2020 | 8.42% | 5.60% | 0.97x | 1.55x | Rs-15.61 Million |
| 2021 | 36.72% | 21.99% | 1.24x | 1.35x | Rs412.73 Million |
| 2022 | 24.55% | 15.72% | 1.15x | 1.36x | Rs295.76 Million |
| 2023 | 9.21% | 7.37% | 0.97x | 1.29x | Rs-17.59 Million |
| 2024 | 15.73% | 12.20% | 0.95x | 1.35x | Rs150.54 Million |
| 2025 | 7.48% | 5.74% | 0.85x | 1.53x | Rs-71.19 Million |
| 2026 | 14.62% | 9.61% | 0.92x | 1.66x | Rs152.04 Million |
Industry Comparison
This section compares NGL Fine-Chem Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $9,471,242,972
- Average return on equity (ROE) among peers: 29.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NGL Fine-Chem Limited (NGLFINE) | Rs3.29 Billion | 15.39% | 0.66x | $184.95 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $17.41 Billion | 35.07% | 0.91x | $5.20 Billion |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $1.98 Billion |
| Sanofi India Limited (SANOFI) | $16.27 Billion | 19.76% | 0.48x | $768.97 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $3.84 Billion | 62.53% | 0.42x | $1.00 Billion |
| SENORES PHARMACEUTICALS L (SENORES) | $9.65 Billion | 11.96% | 0.66x | $698.57 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $646.73 Million | 14.11% | 1.39x | $160.45 Million |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more